高级检索
当前位置: 首页 > 详情页

lncRNA RASSF8-AS1 suppresses the progression of laryngeal squamous cell carcinoma via targeting the miR-664b-3p/TLE1 axis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 2, Dept Otorhinolaryngol, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 1, Dept Otorhinolaryngol, Shijiazhuang 050031, Hebei, Peoples R China [3]Hebei Univ, Affiliated Hosp, Dept Otorhinolaryngol, Baoding 071000, Hebei, Peoples R China
出处:
ISSN:

关键词: long non-coding RNA RASSF8-AS1 laryngeal squamous cell carcinoma competitive endogenous RNA

摘要:
Long non-coding (lnc)RNAs have been found to play a crucial role in tumor progression. The present study aimed to investigate the association between lncRNA RASSF8-AS1 and laryngeal squamous cell carcinoma (LSCC) and the underlying mechanisms. Reverse transcription-quantitative PCR was used to measure the mRNA expression level of RASSF8-AS1, microRNA(miR)-664b-3p and transducin-like enhancer of split 1 (TLE1) in LSCC. The associations between RASSF8-AS1 and miR-664b-3p, and between miR-664b-3p and TLE1 were investigated using a dual luciferase reporter assay, while the former was further verified using an RNA immunoprecipitation (RIP) assay. The association between RASSF8-AS1 and miR-664b-3p on cell biological functions was investigatedin vitrousing MTS, colony formation and Transwell assays. The RASSF8-AS1 mRNA expression level was decreased in LSCC cell lines and carcinoma tissues, while overexpression of RASSF8-AS1 reduced the migration, invasion and proliferation abilities of LSCC cells. Furthermore, luciferase and RIP assays confirmed that RASSF8-AS1 was a competitive endogenous (ce)RNA by sponging miR-664b-3p to activate TLE1. miR-664b-3p was negatively modulated by RASSF8-AS1; however, TLE1 was positively regulated by RASSF8-AS1. Functionally, RASSF8-AS1 acted as a ceRNA to upregulate TLE1 by sponging miR-664b-3p. In conclusion, the RASSF8-AS1/miR-664b-3p/TLE1 axis acts by suppressing LSCC progression and may provide a novel insight for the molecular mechanism of LSCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q3 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 2, Dept Otorhinolaryngol, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Hosp 2, Dept Otorhinolaryngol, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department ofOtorhinolaryngology, The Second Hospital of Hebei MedicalUniversity, 215 Heping West Road, Shijiazhuang, Hebei 050000,P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15100 今日访问量:0 总访问量:960 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号